Arrowstreet Capital’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-69,367
| Closed | -$33.8M | – | 2103 |
|
|
2025
Q4 | $33.8M | Sell |
69,367
-139,168
| -67% | -$64.8M | 0.02% | 592 |
|
|
2025
Q3 | $87.4M | Sell |
208,535
-130,557
| -39% | -$43.9M | 0.06% | 318 |
|
|
2025
Q2 | $97.4M | Sell |
339,092
-59,138
| -15% | -$17.7M | 0.07% | 266 |
|
|
2025
Q1 | $123M | Sell |
398,230
-144,215
| -27% | -$49.4M | 0.1% | 189 |
|
|
2024
Q4 | $191M | Sell |
542,445
-99,154
| -15% | -$36.4M | 0.15% | 127 |
|
|
2024
Q3 | $230M | Buy |
641,599
+202,915
| +46% | +$68.5M | 0.2% | 99 |
|
|
2024
Q2 | $140M | Buy |
438,684
+340,735
| +348% | +$90.2M | 0.12% | 144 |
|
|
2024
Q1 | $22.5M | Buy |
97,949
+87,784
| +864% | +$19.8M | 0.02% | 472 |
|
|
2023
Q4 | $2.23M | Sell |
10,165
-32,681
| -76% | -$7.53M | ﹤0.01% | 945 |
|
|
2023
Q3 | $9.68M | Buy |
+42,846
| New | +$9.87M | 0.01% | 524 |
|
|
2023
Q1 | – | Sell |
-188,974
| Closed | -$52.6M | – | 1540 |
|
|
2022
Q4 | $52.6M | Buy |
188,974
+37,158
| +24% | +$9.38M | 0.07% | 227 |
|
|
2022
Q3 | $31.8M | Sell |
151,816
-22,368
| -13% | -$5M | 0.05% | 294 |
|
|
2022
Q2 | $41M | Buy |
174,184
+169,291
| +3,460% | +$34.4M | 0.06% | 250 |
|
|
2022
Q1 | $878K | Sell |
4,893
-126,035
| -96% | -$24M | ﹤0.01% | 955 |
|
|
2021
Q4 | $28.3M | Sell |
130,928
-86,072
| -40% | -$16.9M | 0.03% | 404 |
|
|
2021
Q3 | $40.1M | Buy |
217,000
+97,100
| +81% | +$19.1M | 0.05% | 364 |
|
|
2021
Q2 | $21.5M | Buy |
+119,900
| New | +$22.8M | 0.03% | 578 |
|
|
2020
Q3 | – | Sell |
-24,290
| Closed | -$2.94M | – | 2531 |
|
|
2020
Q2 | $2.94M | Buy |
+24,290
| New | +$2.73M | 0.01% | 1291 |
|
|
2020
Q1 | – | Sell |
-554,264
| Closed | -$48.8M | – | 2131 |
|
|
2019
Q4 | $48.8M | Sell |
554,264
-112,568
| -17% | -$9.91M | 0.11% | 175 |
|
|
2019
Q3 | $53.2M | Sell |
666,832
-118,628
| -15% | -$9.55M | 0.12% | 176 |
|
|
2019
Q2 | $61.3M | Buy |
785,460
+466,617
| +146% | +$43.6M | 0.14% | 155 |
|
|
2019
Q1 | $37.4M | Buy |
318,843
+295,937
| +1,292% | +$34.5M | 0.09% | 232 |
|
|
2018
Q4 | $2.49M | Buy |
+22,906
| New | +$2.66M | 0.01% | 733 |
|
|
2017
Q2 | – | Sell |
-8,600
| Closed | -$1.16M | – | 1347 |
|
|
2017
Q1 | $1.16M | Buy |
+8,600
| New | +$1.3M | ﹤0.01% | 943 |
|
|
2016
Q4 | – | Sell |
-14,673
| Closed | -$1.73M | – | 2514 |
|
|
2016
Q3 | $1.73M | Buy |
+14,673
| New | +$1.76M | 0.01% | 960 |
|
|
2016
Q1 | – | Sell |
-72,807
| Closed | -$11.4M | – | 1544 |
|
|
2015
Q4 | $11.4M | Sell |
72,807
-16,227
| -18% | -$2.36M | 0.05% | 327 |
|
|
2015
Q3 | $11.7M | Buy |
89,034
+33,808
| +61% | +$5.42M | 0.06% | 306 |
|
|
2015
Q2 | $9.61M | Buy |
55,226
+33,040
| +149% | +$5.94M | 0.05% | 276 |
|
|
2015
Q1 | $3.83M | Buy |
+22,186
| New | +$3.38M | 0.02% | 467 |
|
|
2014
Q3 | – | Sell |
-45,026
| Closed | -$3.98M | – | 1129 |
|
|
2014
Q2 | $3.98M | Sell |
45,026
-329,894
| -88% | -$31.7M | 0.02% | 460 |
|
|
2014
Q1 | $35.3M | Sell |
374,920
-201,903
| -35% | -$20.6M | 0.21% | 115 |
|
|
2013
Q4 | $65.2M | Sell |
576,823
-95,243
| -14% | -$8.59M | 0.35% | 81 |
|
|
2013
Q3 | $53M | Hold |
672,066
| – | – | 0.34% | 76 |
|
|
2013
Q2 | $44.2M | Buy |
+672,066
| New | +$43.3M | 0.33% | 82 |
|
Other funds holding UTHR
ACA
VPM
VCM
Arrowstreet Capital's UTHR Position: Q1 2026 in Review
Arrowstreet Capital sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 69,367 shares — an estimated $33.8M sold.
Arrowstreet Capital first reported a position in UTHR in Q2 2013 and held it in 34 quarters. The position peaked at $230M in Q3 2024. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- Arrowstreet Capital reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
- Arrowstreet Capital sold 69,367 United Therapeutics shares in Q1 2026, an estimated $33.8M.
- Arrowstreet Capital first reported a position in United Therapeutics in Q2 2013 and held it in 34 quarters.
- Arrowstreet Capital's United Therapeutics position peaked at $230M in Q3 2024.
- 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.